Patients' self-estimated likelihood of taking a statin as prescribed after different types of prognostic information

Atherosclerosis

Volumn 212, Issue 2, 2010, Pages 586-588

  Roshan, F ^a   Saeed, M ^a   Agewall, S ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Adherence; Compliance; Information; Prevention; Statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG USE; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; RISK REDUCTION; SELF EVALUATION;

AGED; CARDIOVASCULAR DISEASES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROGNOSIS; QUESTIONNAIRES; RISK; SELF CARE;

EID: 77957700638     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.07.020     Document Type: Article

References (16)

1. Bassand J.P., Hamm C.W., et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007, 28:1598-1660. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology.
2. Van de Werf F., Bax J., Betriu A., et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008, 29:2909-2945.
3. Siegel D., Lopez J., Meier J. Use of cholesterol-lowering medications in the United States from 1991 to 1997. Am J Med 2000, 108:496-499.
4. Ma J., Sehgal N.L., Ayanian J.Z., Stafford R.S. National trends in statin use by coronary heart disease risk category. PLoS Med 2005, 2:e123.
5. Simons L.A., Levis G., Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996, 164:208-211.
6. Simons L.A., Simons J., McManus P., Dudley J. Discontinuation rates for use of statins are high. BMJ 2000, 320:1583-1584.
7. Pearson T.A., Peters T.D. The treatment gap in coronary artery disease and heart failure: community standards and the post-discharge patient. Am J Cardiol 1997, 80:45H-52H.
8. Prevention of Cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: The Long Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998, 339:1349-1357.
9. Insull W. The problem of compliance to cholesterol altering therapy. J Intern Med 1997, 241:317-325.
10. Yilmaz M.B., Pinar M., Naharci I., et al. Being well-informed about statin is associated with continuous adherence and reaching targets. Cardiovasc Drugs Ther 2005, 19:437-440.
11. Randomised trial of cholesterol lowering in 4 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389. Scandinavian Simvastatin Survival Study Group.
12. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
13. Tolmie E.P., Lindsay G.M., Kerr S.M., Brown M.R., Ford I., Gaw A. Patients' perspectives on statin therapy for treatment of hypercholesterolaemia; a qualitative study. Eur J Cardiovasc Nurs 2003, 2:141-149.
14. Schedlbauer A., Schroeder K., Peters T.J., Fahey T. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev 2004, (4):CD004371.
15. Avorn J., Monette J., Lacour A., et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998, 279:1458-1462.
16. McGinnis B.D., Olson K.L., Delate T.M., Stolcpart R.S. Statin adherence and mortality in patients enrolled in a secondary prevention program. Am J Manage Care 2009, 15:689-695.